Lonza extends accelerated DNA-to-IND services to complex biologics and high-concentration formulations
Company / institutional announcement · Lonza
Source published: · Event / reporting date: 2026-10-13
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Lonza expanded its accelerated DNA-to-IND offering to bispecific antibodies, Fc-fusion proteins, and high-concentration drug product formulations. The program coordinates drug substance and drug product development and manufacturing. Lonza states that eligible programs can deliver toxicology drug substance in as little as three months and reach IND readiness in six months; these are supplier-reported timelines.
Why it may matter
Developers may benefit from addressing formulation, analytics, and manufacturing together earlier. Whether the advertised timelines apply still depends on the molecule, program assumptions, and contracted deliverables.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections